Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Royalty Pharma plc | Director | Class A Ordinary Shares | 46.2K | $1.4M | $30.23 | Jun 7, 2024 | Direct |
Structure Therapeutics Inc. | Director | Stock option (right to buy) | 75K | $598K | $7.97 | Aug 3, 2023 | Direct |
GILEAD SCIENCES, INC. | Director | Common Stock | 2.82K | $183K | $64.92 | May 8, 2024 | Direct |
Structure Therapeutics Inc. | Director | Share Option (right to buy) | 33.6K | Jun 25, 2024 | Direct | ||
GILEAD SCIENCES, INC. | Director | Non-qualified Stock Option (Right to Buy) | 12.6K | May 8, 2024 | Direct | ||
Global Blood Therapeutics, Inc. | President and CEO, Director | Common Stock | 0 | $46.99 | Oct 5, 2022 | By Daughter | |
Global Blood Therapeutics, Inc. | President and CEO, Director | Common Stock | 0 | $46.99 | Oct 5, 2022 | By Trust 1 | |
Global Blood Therapeutics, Inc. | President and CEO, Director | Common Stock | 0 | $46.99 | Oct 5, 2022 | By Trust 2 | |
Global Blood Therapeutics, Inc. | President and CEO, Director | Common Stock | 0 | $46.99 | Oct 5, 2022 | By Trust 3 | |
Global Blood Therapeutics, Inc. | President and CEO, Director | Common Stock | 0 | $46.99 | Oct 5, 2022 | Direct | |
Global Blood Therapeutics, Inc. | President and CEO, Director | Restricted Stock Units | 0 | Oct 5, 2022 | Direct | ||
Global Blood Therapeutics, Inc. | President and CEO, Director | Stock Option (Right to Buy) | 0 | Oct 5, 2022 | Direct | ||
Seagen Inc. | Director | Common Stock | 0 | $229.00 | Dec 14, 2023 | Direct | |
Seagen Inc. | Director | Restricted Stock Units | 0 | $229.00 | Dec 14, 2023 | Direct | |
Seagen Inc. | Director | Stock Options (Right to Buy) | 0 | Dec 14, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
GPCR | Structure Therapeutics Inc. | Jun 25, 2024 | 1 | $0 | 4 | Jun 27, 2024 | Director |
RPRX | Royalty Pharma plc | Jun 7, 2024 | 1 | $0 | 4 | Jun 10, 2024 | Director |
GILD | GILEAD SCIENCES, INC. | May 8, 2024 | 2 | $0 | 4 | May 9, 2024 | Director |
GILD | GILEAD SCIENCES, INC. | Feb 2, 2024 | 2 | $0 | 4 | Feb 6, 2024 | Director |
GILD | GILEAD SCIENCES, INC. | Feb 1, 2024 | 0 | $0 | 3 | Feb 6, 2024 | Director |
SGEN | Seagen Inc. | Dec 14, 2023 | 6 | -$974K | 4 | Dec 15, 2023 | Director |
GPCR | Structure Therapeutics Inc. | Aug 3, 2023 | 1 | $0 | 4 | Aug 4, 2023 | Director |
GPCR | Structure Therapeutics Inc. | Aug 3, 2023 | 0 | $0 | 3 | Aug 4, 2023 | Director |
RPRX | Royalty Pharma plc | Jun 23, 2023 | 1 | $0 | 4 | Jun 26, 2023 | Director |
SGEN | Seagen Inc. | May 31, 2023 | 1 | $0 | 4 | Jun 2, 2023 | Director |
GBT | Global Blood Therapeutics, Inc. | Oct 5, 2022 | 18 | $0 | 4 | Oct 6, 2022 | President and CEO, Director |
GBT | Global Blood Therapeutics, Inc. | Sep 27, 2022 | 6 | $300K | 4 | Sep 29, 2022 | President and CEO, Director |
GBT | Global Blood Therapeutics, Inc. | Sep 1, 2022 | 5 | -$627K | 4 | Sep 6, 2022 | President and CEO, Director |
GBT | Global Blood Therapeutics, Inc. | Aug 1, 2022 | 4 | -$325K | 4 | Aug 3, 2022 | President and CEO, Director |
RPRX | Royalty Pharma plc | Jun 24, 2022 | 1 | $0 | 4 | Jun 24, 2022 | Director |
SGEN | Seagen Inc. | May 13, 2022 | 2 | $0 | 4 | May 17, 2022 | Director |
GBT | Global Blood Therapeutics, Inc. | Mar 1, 2022 | 7 | -$100K | 4 | Mar 3, 2022 | President and CEO, Director |
GBT | Global Blood Therapeutics, Inc. | Feb 1, 2022 | 5 | -$309K | 4 | Feb 3, 2022 | President and CEO, Director |
GBT | Global Blood Therapeutics, Inc. | Sep 1, 2021 | 3 | -$140K | 4 | Sep 3, 2021 | President and CEO, Director |
GBT | Global Blood Therapeutics, Inc. | Aug 1, 2021 | 5 | -$406K | 4/A | Sep 24, 2021 | President and CEO, Director |
RPRX | Royalty Pharma plc | Jun 25, 2021 | 1 | $0 | 4 | Jun 29, 2021 | Director |
SGEN | Seagen Inc. | May 14, 2021 | 2 | $0 | 4 | May 18, 2021 | Director |
GBT | Global Blood Therapeutics, Inc. | Jul 1, 2016 | 1 | -$84.4K | 4/A | Jan 6, 2022 | President and CEO, Director |